From the 5-fluorouracil-, doxorubicin- and cyclophosphamide-induced DNA repair viewpoint, the genotypes of either ERCC1 rs11615 or rs3212986 may cause the differential responses to these drugs in TNBC or other subtypes of breast cancer patients [51]. This evidence concerns the gene ERCC1 and breast carcinoma.